A Retrospective Study of Clinical Outcomes for Patients with Esophageal Cancer Who Were Treated with Radiotherapy Alone.
Gastrointest Tumors
; 10(1): 57-66, 2023.
Article
in En
| MEDLINE
| ID: mdl-39015760
ABSTRACT
Introduction:
Patients with esophageal cancer who are in a poor general condition receive radiotherapy alone, but outcomes are often unsatisfactory. The aim of this study was to clarify recent outcomes of radiotherapy alone for esophageal cancer.Methods:
Patients who underwent 50 Gy or more of radiotherapy without chemotherapy were retrospectively reviewed. Endpoints were overall survival (OS), disease-specific survival (DSS), local control (LC), and progression-free survival (PFS). Survival curves were drawn using the Kaplan-Meier method, and predictors were analyzed using the Cox proportional hazards model.Results:
Sixty-nine patients were included. The median follow-up period was 17.9 months. The 5-year OS, DSS, LC, and PFS rates were 33.2%, 49.8%, 46.2%, and 16.8%, respectively. In the multivariate Cox proportional hazard model, clinical stage was a significant predictor for OS (hazard ratio [HR] 4.42, 95% confidence interval [CI] 1.80-11.17, p = 0.001), DSS (HR 2.08, 95% CI 1.43-3.12, p = 0.0001), LC (HR 1.86, 95% CI 1.28-2.74, p = 0.001), and PFS (HR 1.65, 95% CI 1.25-2.18, p = 0.0004). Radiation dose was a significant predictor for LC (HR 0.87, 95% CI 0.78-0.97, p = 0.018) and tumor location was a significant predictor for PFS (HR 1.55, 95% CI 1.10-2.19, p = 0.018). In subgroup analysis, the 5-year OS, DSS, LC, and PFS rates for stage I were 60.0%, 80.0%, 71.9%, and 46.1%, respectively.Conclusions:
Stage, radiation dose, and tumor location are significant predictors for outcomes. Patients with stage I esophageal cancer can be cured by radiotherapy alone.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Gastrointest Tumors
Year:
2023
Document type:
Article
Affiliation country:
Japan